Share on StockTwits

Regeneron Pharmaceuticals (NASDAQ:REGN) SVP Neil Stahl unloaded 2,841 shares of Regeneron Pharmaceuticals stock on the open market in a transaction dated Friday, August 8th. The stock was sold at an average price of $340.60, for a total transaction of $967,644.60. Following the completion of the transaction, the senior vice president now directly owns 25,173 shares in the company, valued at approximately $8,573,924. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

A number of analysts have recently weighed in on REGN shares. Analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $349.00 to $373.00 in a research note on Wednesday. They now have an “outperform” rating on the stock. Separately, analysts at Roth Capital reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday. Finally, analysts at Deutsche Bank raised their price target on shares of Regeneron Pharmaceuticals from $410.00 to $425.00 in a research note on Tuesday. They now have a “buy” rating on the stock. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Regeneron Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $345.94.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 0.12% on Friday, hitting $338.32. The stock had a trading volume of 627,524 shares. Regeneron Pharmaceuticals has a 52-week low of $227.64 and a 52-week high of $352.49. The stock has a 50-day moving average of $306.3 and a 200-day moving average of $306.3. The company has a market cap of $33.964 billion and a price-to-earnings ratio of 96.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.17. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter in the previous year, the company posted $1.73 earnings per share. The company’s revenue for the quarter was up 45.4% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals will post $10.04 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.